No, Synjardy Does Not Contain Farxiga
Synjardy contains empagliflozin (not dapagliflozin, which is the active ingredient in Farxiga), combined with metformin. 1
Key Distinction Between These Medications
While both medications are SGLT2 inhibitors used to treat type 2 diabetes, they contain different active ingredients:
- Synjardy: Contains empagliflozin + metformin 1
- Farxiga: Contains dapagliflozin (a different SGLT2 inhibitor)
What Synjardy Actually Contains
Synjardy is a fixed-dose combination tablet with two active ingredients 1:
- Empagliflozin (an SGLT2 inhibitor) - available in doses of 5 mg, 10 mg, 12.5 mg, or 25 mg
- Metformin hydrochloride (a biguanide) - available in doses of 500 mg or 1,000 mg
The empagliflozin component works by inhibiting SGLT2 in the kidneys, increasing urinary glucose excretion and reducing sodium reabsorption. The metformin component decreases hepatic glucose production and improves insulin sensitivity 1.
Clinical Implications
Both empagliflozin (in Synjardy) and dapagliflozin (Farxiga) belong to the same drug class and have similar mechanisms of action, but they are distinct molecules with separate FDA approvals. According to current diabetes management guidelines, SGLT2 inhibitors like empagliflozin show benefits for cardiovascular outcomes, heart failure, and chronic kidney disease 2.
The combination of empagliflozin with metformin in Synjardy provides complementary glycemic control through different mechanisms, with empagliflozin offering additional cardiometabolic benefits including weight reduction and blood pressure lowering 3, 4.